BMJ:HbA1c水平可以作为1型糖尿病儿童和成人视网膜病变和肾病的危险因素

2019-09-08 不详 MedSci原创

本项研究的目的是评估糖尿病患者血红蛋白(HbA1c)<6.5%的最低目标水平是否与儿童和1型糖尿病成人视网膜病变和肾病的风险较低有关。

背景及目的:
本项研究的目的是评估糖尿病患者血红蛋白(HbA1c)<6.5%的最低目标水平是否与儿童和1型糖尿病成人视网膜病变和肾病的风险较低有关。

方法:
 研究人员收集了瑞典1998年1月1日至2017年12月31日间共10398名患有1型糖尿病儿童和成人,主要观察结果是不同水平的HbA 1c下的视网膜病变和肾病的相对风险(优势比)。

结果:
本项研究的结果显示受试者的平均年龄为14.7岁(女性占43.4%),平均糖尿病病程为1.3年,平均HbA1c水平为8.0%(63.4 mmol / mol)。在调整年龄,性别,糖尿病持续时间,血压,血脂水平,体重指数和吸烟后,平均HbA1c <6.5%(<48 mmol / mol)的比值比为6.5-6.9%,较高的HBA1c对于增生前的糖尿病性视网膜病变或更差的危险比为3.29(0.99至10.96,P = 0.05),对于增生糖尿病视网膜病变的危险比为2.48(0.71至8.62,P = 0.15),与HbA1c相比水平6.5-6.9%,HbA 1c水平7.0-7.4%(53-57 mmol / mol)与任何视网膜病变(1.31,1.05至1.64,P = 0.02)和微量白蛋白尿(1.55,1.03至2.32, P = 0.03),增殖性视网膜病变(5.98,2.10至17.06,P <0.001)和大量白蛋白尿(3.43,1.14至10.26,P = 0.03)的风险在HbA1c水平> 8.6%(> 70mmol / mol)时增加。

结论:
视网膜病变和肾病的风险在HbA 1c水平<6.5%时无差异,严重并发症的风险主要发生在HbA 1c水平> 8.6%时,但轻度并发症在HbA 1c水平> 7.0%时。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2015956, encodeId=306e2015956b3, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Aug 16 05:58:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848835, encodeId=8a3b184883525, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue May 12 13:58:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270212, encodeId=130112e021209, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Sep 10 00:58:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413994, encodeId=bc1c14139940e, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Tue Sep 10 00:58:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042682, encodeId=e95b1042682cd, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Sep 08 12:58:00 CST 2019, time=2019-09-08, status=1, ipAttribution=)]
    2020-08-16 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=2015956, encodeId=306e2015956b3, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Aug 16 05:58:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848835, encodeId=8a3b184883525, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue May 12 13:58:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270212, encodeId=130112e021209, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Sep 10 00:58:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413994, encodeId=bc1c14139940e, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Tue Sep 10 00:58:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042682, encodeId=e95b1042682cd, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Sep 08 12:58:00 CST 2019, time=2019-09-08, status=1, ipAttribution=)]
    2020-05-12 gaoxiaoe
  3. [GetPortalCommentsPageByObjectIdResponse(id=2015956, encodeId=306e2015956b3, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Aug 16 05:58:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848835, encodeId=8a3b184883525, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue May 12 13:58:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270212, encodeId=130112e021209, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Sep 10 00:58:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413994, encodeId=bc1c14139940e, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Tue Sep 10 00:58:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042682, encodeId=e95b1042682cd, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Sep 08 12:58:00 CST 2019, time=2019-09-08, status=1, ipAttribution=)]
    2019-09-10 zutt
  4. [GetPortalCommentsPageByObjectIdResponse(id=2015956, encodeId=306e2015956b3, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Aug 16 05:58:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848835, encodeId=8a3b184883525, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue May 12 13:58:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270212, encodeId=130112e021209, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Sep 10 00:58:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413994, encodeId=bc1c14139940e, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Tue Sep 10 00:58:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042682, encodeId=e95b1042682cd, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Sep 08 12:58:00 CST 2019, time=2019-09-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2015956, encodeId=306e2015956b3, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Aug 16 05:58:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848835, encodeId=8a3b184883525, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue May 12 13:58:00 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270212, encodeId=130112e021209, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Sep 10 00:58:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413994, encodeId=bc1c14139940e, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Tue Sep 10 00:58:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042682, encodeId=e95b1042682cd, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Sep 08 12:58:00 CST 2019, time=2019-09-08, status=1, ipAttribution=)]
    2019-09-08 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

J Diabetes:外周动脉术前HbA1c水平或可预测术后死亡率

一项最新研究表明,外周动脉疾病患者接受手术治疗前的HbA1c水平或可预测长期死亡风险。

Diabetes Obes Metab:杜拉鲁肽可降低2型糖尿病患者的HbA1c

对8项AWARD研究的事后分析表明,在任何研究中,基线BMI不影响杜拉鲁肽的相对治疗效果,如通过HbA1c从基线的变化来衡量时。杜拉鲁肽是2型糖尿病患者的有效治疗选择,无论其基线BMI如何。

Diabetic Med:控制HbA1c,低碳水化合物饮食是否有效?

目前,人们对碳水化合物在控制体重和血糖方面的作用非常感兴趣。然而,美国和欧洲的糖尿病指南并未对碳水化合物的摄入量给出具体的建议,而是强调监测总的碳水化合物是实现血糖控制目标的关键战略。

JACC:生活方式、HbA1c等风险因素控制可改善患者生存率

糖化血红蛋白A1c(HbA1c)控制能否作为稳定性缺血性心脏病(SIHD)和糖尿病(DM)患者综合危险因素管理的一部分仍存在争议。G.B. John Mancini等研究者发表于JACC的一项研究目的是确定1年时更多的可控风险因素,包括HbA1c,是否影响DM和SIHD患者的生存率。

Stroke:机械性血栓切除术治疗的大血管闭塞患者HbA1c与临床结局的关系

这些结果表明,在采用MT治疗的大血管闭塞患者中,较高HbA1c水平是AIS后3个月不良预后的独立预测因子,特别是在血管再通的患者中,并且可能增加AIS后死亡和早期临床恶化的风险。

CDS2018:金标准也须与时俱进:看CGM如何超越HbA1c,助力血糖全面管理

2018年11月30日,在中华医学会糖尿病学分会第二十二次全国学术会议(CDS2018)上,上海交通大学附属第六人民医院包玉倩教授从血糖管理指标方面分析了持续葡萄糖监测(CGM)相较于糖化血红蛋白(HbA1c)用于血糖控制与评估的优势,为广大参会者更深入了解CGM提供了重要信息。